BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mercury Therapeutics, Inc. Outlicenses Research Products Applications of AMP-Activated Protein Kinase to Millipore Corporation (MIL)


5/19/2009 11:19:39 AM

WOBURN, MA--(Marketwire - May 19, 2009) - Mercury Therapeutics, a privately held biotech company based in Woburn, Massachusetts focusing on the development of AMP-activated protein kinase (AMPK) activators for the development of novel therapeutics for type 2 diabetes, oncology and cardiovascular disease, announced today the signing of a world wide exclusive license with Millipore Corp. of Bedford, Massachusetts for the rights to human AMPK in the field of research products and services.

The AMPK patent was originally licensed by Mercury Therapeutics in 2000 from Dartmouth College. The patent is co-invented by Dartmouth Professor Dr. Lee Witters and Dr. Bruce Kemp, his collaborator at St. Vincent's Institute for Medical Research in Melbourne, Australia. The transaction includes an upfront license fee, royalties on net sales, and sharing of all sublicense revenue for the life of the Agreement.

"This association with Millipore promises to advance significantly the field of AMPK-directed therapies," says Lee A. Witters MD, Eugene W. Leonard 1921 Professor of Medicine & Biochemistry, Dartmouth Medical School, Professor of Biological Sciences, Dartmouth College.

Alla Kan, Director of Dartmouth's Technology Transfer Office, says: "This technology, capable of alleviating symptoms of so many diseases, has always been seen by us as one of our crown jewels, and now with this exciting development, its time has come."

Katan Associates has advised Mercury on this transaction.


For further information please contact:
Katan Associates
(310) 374 0808



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES